Buruli Ulcer Lesions in HIV-Positive Patient

To the Editor: Mycobacterium ulcerans disease (Buruli ulcer) is a neglected and emerging tropical disease (1). It often leads to extensive destruction of skin and soft tissue with the formation of large ulcers (2). In 2004, the World Health Organization (WHO) recommended the combination treatment of rifampin/streptomycin for patients with this disease (3). According to WHO, development of new antimicrobial drug treatment is one of the major advances since the establishment of the Global Buruli Ulcer Initiative (I). Treatment with rifampin/streptomycin for ≥4 weeks can inhibit the growth of M. ulcerans in preulcerative lesions (4). In other patients, despite 4 weeks of treatment, lesions may deteriorate. Whether this treatment is less efficacious in persons with HIV infection is unknown.

In August 2008, a 35-year-old man was referred to the Medical Center of the Democratic Republic of Congo for assessment of chronic ulcers. Lesions had appeared 12 months earlier when the patient was living in Kafufu/Luremo, a new endemic focus (5). Tissue specimens were subjected to Ziehl-Neelsen staining, culture, and PCR. All results were positive for M. ulcerans. Histopathologic analysis of formalin-fixed tissue confirmed the diagnosis of active Buruli ulcer. We treated the patient with a combination of rifampin (10 mg/kg/day, orally) and streptomycin (15 mg/kg/day, by intramuscular injection). Wound dressings containing an aqueous solution of chloramine/metronidazole/nitrofurantoin were changed daily (6). For logistic reasons, surgery (large excision) under general anesthesia was not possible.

Characteristics of the patient are shown in the online Technical Appendix (www.cdc.gov/EID/content/16/4/738-Techapp.pdf). At the start of treatment, the patient had a large ulcer on the right leg and thigh, a nodule 2 cm in diameter on the left thigh, and a plaque 8 cm in diameter on the left thigh. After 2 weeks of treatment, the size of the large ulcer had increased. After 4 weeks, the nodule became an ulcer 6 cm in diameter, and the plaque became a large ulcer 15 cm in diameter with a satellite ulcer 2 cm in diameter. After 8 weeks, we observed enlargement of all lesions and the appearance of an ulcer on the left wrist. Treatment was continued for an additional 4 weeks (total 12 weeks). Radiologic investigation did not disclose any bone destruction.

The patient was positive for HIV by the Determine HIV-1/2 test (Abbott Laboratories, Dainabot Co. Ltd., Tokyo, Japan), the Uni-Gold HIV test (Trinity Biotech PLC, Bray, Ireland), and the Genie II HIV-1/HIV-2 test (Bio-Rad, Marnes-la-Cochette, France). Results of PCR for M. ulcerans and Ziehl-Neelsen staining were positive for all specimens obtained during the 8 weeks of initial treatment. The patient died 2 weeks after treatment ended, just when antiretroviral treatment had been scheduled to begin.

Although the patient did not respond clinically to treatment with rifampin/streptomycin, whether the treatment also failed microbiologically is more difficult to prove. Results of PCRs performed during treatment remained positive. However, PCR does not differentiate between living and dead M. ulcerans bacteria. Therefore, our positive results suggest, but do not prove, treatment failure. The positive culture after 2 weeks of treatment also suggests treatment failure but cultures obtained at 4 and 8 weeks were contaminated. However, culturing M. ulcerans bacteria is difficult, especially if samples must be transported (7).

Patients with Buruli ulcer may also be infected with HIV. In a study conducted during January 2002–Au-
Editor:

Hantaviruses are rodent-borne negative-sense RNA viruses belonging to the Bunyaviridae family, genus Hantavirus. Since the first report of a hantavirus in 1993 in the United States (1), different viruses belonging to this genus have been reported in the Americas (2–5). These New World viruses are responsible for a disease called hantavirus pulmonary syndrome (HPS), a respiratory illness caused by the inhalation of dust contaminated by rodent feces or urine containing the virus (6–8).

Until recently, no information was available concerning the presence of hantaviruses in French Guiana, a French overseas department (administrative unit) in South America. Nevertheless, the description of atypical pneumonia cases not related to any known etiologic agent and the identification of hantavirus reservoirs in neighboring countries led us to con-
# Buruli Ulcer Lesions in HIV-Positive Patient

## Technical Appendix

Characteristics of HIV-positive patient with Buruli ulcer during treatment with rifampin/streptomycin, Democratic Republic of Congo*

<table>
<thead>
<tr>
<th>Period of treatment</th>
<th>Lesions</th>
<th>Clinical features</th>
<th>Results of microbiologic and histologic analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1 (start of treatment)</td>
<td><img src="image1" alt="Lesion Image" /></td>
<td>Large ulcer (right leg and thigh), nodule 2 cm in diameter (left thigh), and plaque 8 cm in diameter (left thigh)</td>
<td>ZN staining (ATS) (7) 2+, PCR positive, culture contaminated, active Buruli ulcer lesions</td>
</tr>
<tr>
<td>2 weeks</td>
<td><img src="image2" alt="Lesion Image" /></td>
<td>Increase in size of large ulcer (right leg and thigh)</td>
<td>ZN staining (ATS) 4+, PCR positive, culture positive, ND</td>
</tr>
<tr>
<td>4 weeks</td>
<td><img src="image3" alt="Lesion Image" /></td>
<td>Nodule 2 cm in diameter (left thigh) becomes an ulcer 6 cm in diameter, plaque 8 cm in diameter (left thigh) becomes a large ulcer 15 cm in diameter, and appearance of an ulcer 2 cm in diameter</td>
<td>ZN (ATS) 1+, PCR positive, culture contaminated, ND</td>
</tr>
</tbody>
</table>
8 weeks | Increase in size of all lesions and appearance of an ulcer on the left wrist | ZN (ATS) 4+, PCR positive, culture contaminated, ND

*ZN, Ziehl-Neelsen; ATS, American Thoracic Society; ND, histologic analysis not done.

**Reference**